SOUTH EASTON, Mass., July 1 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO "PBI") today announced that scientists from the New York University ("NYU") School of Medicine and the Brooklyn Hospital Center presented results yesterday on advances they made in the areas of breast and colon cancer, stroke, and in vitro fertilization ("IVF"). The results were generated in studies using PBI's patented pressure cycling technology ("PCT") and patent-pending PCT-dependent ProteoSolve-LRS protein extraction kit. The presentations were made at the 2nd Annual Advances in Biomolecular Engineering: Protein Design Symposium, sponsored by the New York Academy of Sciences.
Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology) and principle investigator for the research studies, commented: "PCT is critical to our work. This novel, cutting-edge technology consistently gives us rapid and reliable extraction of proteins from our important samples. In addition -- and this is very exciting -- PCT has given us the additional extraordinary benefits of not only greater protein yield, but the extraction of proteins not previously identified in these types of samples. Consequently, we believe that the use of PCT, more than the use of any extraction technology available today, could lead to the discovery of new biomarkers for cancer and stroke, which in turn could lead to the development of new diagnostics and therapeutics to combat these diseases."
Dr. Pevsner continued: "Many IVF live births result in twins, triplets, and higher order births. Unfortunately, fetuses and mothers of multiple and high-order multiple pregnancies have increased morbidity and mortality. To combat this, more single embryo transfers are needed. To this end, we have been interested in identifying biomarkers for embryo viability and competence. Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth media only seen in competent embryos. These proteins may prove to be biomarkers that can enhance selection and result in more live births from single embryo transfers. These are very exciting results."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.
Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the Brooklyn Hospital Center and the NYU School of Medicine, the results of their studies having been presented at the Annual Scientific Meeting of the American College of Gastroenterology. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Momeni and her colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for colon cancer; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
CONTACT:
Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 580-1818